Novo Nordisk Shares Signal a Turnaround with Key FDA Approval

Investors in Novo Nordisk have reason for renewed optimism following a challenging period. The Danish pharmaceutical giant received a significant, market-moving endorsement from U.S. regulators just before the Christmas holiday. The green light for an oral version of its weight-loss drug, Wegovy, provides the company with a crucial strategic edge against its main competitor, Eli Lilly, and could trigger a fundamental reassessment of its stock.

The U.S. Food and Drug Administration (FDA) granted approval on December 22 for a tablet form of the active ingredient semaglutid. This decision represents the first authorized GLP-1 medication specifically developed for weight reduction that comes in a pill format. The market’s response was Read more...